CLINICAL TRIALS PROFILE FOR CEFUROXIME AXETIL

All Clinical Trials for CEFUROXIME AXETIL

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000752 ↗	Preventing Frequent Sinus Infections in HIV-Infected Patients	Withdrawn	Adams Laboratories	Phase 2	1969-12-31	To evaluate the additional effectiveness of an anti-inflammatory nasal spray ( beclomethasone dipropionate ) and a broad spectrum antibiotic ( cefuroxime axetil ) over decongestant ( Deconsal II ) alone, when these agents are given individually or in combination for the prevention of recurrent paranasal sinus infection in patients with HIV infection. To compare the clinical utility of paranasal sinus radiographs with computed tomograms (CTs) in the evaluation and management of HIV-infected patients with recurrent paranasal sinus infection. To determine relevant prognostic factors and the microbiologic etiology of maxillary sinusitis in this patient population. Sinusitis is common among HIV-infected patients and is likely to be recurrent or refractory to traditional therapy, particularly in patients with advanced immunosuppression. An intervention aimed at prevention of recurrent sinus disease in HIV-infected patients appears to be warranted.
NCT00000752 ↗	Preventing Frequent Sinus Infections in HIV-Infected Patients	Withdrawn	Glaxo Wellcome	Phase 2	1969-12-31	To evaluate the additional effectiveness of an anti-inflammatory nasal spray ( beclomethasone dipropionate ) and a broad spectrum antibiotic ( cefuroxime axetil ) over decongestant ( Deconsal II ) alone, when these agents are given individually or in combination for the prevention of recurrent paranasal sinus infection in patients with HIV infection. To compare the clinical utility of paranasal sinus radiographs with computed tomograms (CTs) in the evaluation and management of HIV-infected patients with recurrent paranasal sinus infection. To determine relevant prognostic factors and the microbiologic etiology of maxillary sinusitis in this patient population. Sinusitis is common among HIV-infected patients and is likely to be recurrent or refractory to traditional therapy, particularly in patients with advanced immunosuppression. An intervention aimed at prevention of recurrent sinus disease in HIV-infected patients appears to be warranted.
NCT00000752 ↗	Preventing Frequent Sinus Infections in HIV-Infected Patients	Withdrawn	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	To evaluate the additional effectiveness of an anti-inflammatory nasal spray ( beclomethasone dipropionate ) and a broad spectrum antibiotic ( cefuroxime axetil ) over decongestant ( Deconsal II ) alone, when these agents are given individually or in combination for the prevention of recurrent paranasal sinus infection in patients with HIV infection. To compare the clinical utility of paranasal sinus radiographs with computed tomograms (CTs) in the evaluation and management of HIV-infected patients with recurrent paranasal sinus infection. To determine relevant prognostic factors and the microbiologic etiology of maxillary sinusitis in this patient population. Sinusitis is common among HIV-infected patients and is likely to be recurrent or refractory to traditional therapy, particularly in patients with advanced immunosuppression. An intervention aimed at prevention of recurrent sinus disease in HIV-infected patients appears to be warranted.
NCT00132938 ↗	PERSPECTIVE: Telithromycin - Acute Exacerbation of Chronic Bronchitis	Completed	Sanofi	Phase 4	2004-01-01	Primary Objective: - The primary objective of the study is to demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in the reduction of Streptococcus pneumoniae (Sp) strains resistant to beta-lactams or macrolides at the Test of Cure (TOC) visit in the sputum of patients with Sp detected at the start of the study (Visit 1). Secondary Objectives: The secondary objectives of the study are: - To demonstrate the superiority of telithromycin over azithromycin and over cefuroxime axetil in achieving clinical cure and Sp eradication success at the Test of Cure visit in patients with Sp detected in sputum specimen at the start of the study (Visit 1); - To compare the clinical cure rates achieved by each treatment group in the penicillin or erythromycin resistant Sp (PERSp) population with the cure rates in the sensitive Sp (SSp) population at the End of Therapy (EOT) and Test of Cure visits; - To compare the effect of telithromycin, azithromycin and cefuroxime axetil at the End of Therapy visit on the presence of Streptococcus pneumoniae strains resistant to beta-lactams or macrolides in the sputum of patients with Sp detected at the start of the study (Visit 1); - To compare the clinical efficacy at the End of Therapy visit and safety at the Test of Cure visit of telithromycin, azithromycin and cefuroxime axetil in the "global" randomized population.
NCT00174811 ↗	Comparative Study to Evaluate the Efficacy and Safety of Telithromycin Given Once Daily Versus Cefuroxime Axetil Given Twice Daily in Children With Middle Ear Infections	Terminated	Sanofi	Phase 3	2005-06-01	The clinical activity of telithromycin vs. cefuroxime in children with acute infections of the middle ear, ages 6 months to 59 months old will be studied.

Clinical Trial Conditions for CEFUROXIME AXETIL

Condition Name

Condition Name for CEFUROXIME AXETIL
Intervention	Trials
Otitis Media	1
Pneumonia	1
Post-Lyme Disease Symptoms	1
Pyelonephritis in Pregnancy	1

Condition MeSH

Condition MeSH for CEFUROXIME AXETIL
Intervention	Trials
Bronchitis, Chronic	2
Glossitis, Benign Migratory	2
Bronchitis	2
Erythema Chronicum Migrans	2

Clinical Trial Locations for CEFUROXIME AXETIL

Trials by Country

Trials by Country for CEFUROXIME AXETIL
Location	Trials
United States	6
France	2
Hungary	1
Tunisia	1
Brazil	1

Trials by US State

Trials by US State for CEFUROXIME AXETIL
Location	Trials
New Jersey	2
Pennsylvania	1
New York	1
California	1
Kentucky	1

Clinical Trial Progress for CEFUROXIME AXETIL

Clinical Trial Phase

Clinical Trial Phase for CEFUROXIME AXETIL
Clinical Trial Phase	Trials
PHASE4	1
Phase 4	2
Phase 3	2

Clinical Trial Status

Clinical Trial Status for CEFUROXIME AXETIL
Clinical Trial Phase	Trials
Completed	5
Terminated	2
Withdrawn	1

Clinical Trial Sponsors for CEFUROXIME AXETIL

Sponsor Name

Sponsor Name for CEFUROXIME AXETIL
Sponsor	Trials
Sanofi	2
PriCara, Unit of Ortho-McNeil, Inc.	2
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	2

Sponsor Type

Sponsor Type for CEFUROXIME AXETIL
Sponsor	Trials
Industry	8
Other	7
NIH	1

Cefuroxime Axetil: Clinical Trials Update, Market Analysis, and Projection

Last updated: April 27, 2026

Cefuroxime axetil (oral prodrug of cefuroxime) is an established, off-patent beta-lactam antibiotic used for respiratory, ENT, and other community-acquired bacterial infections. No current late-stage (Phase 3 or pivotal) development pipeline is visible in public trial registries based on available records, which makes near-term growth dependent on generic supply, formulary positioning, and volume dynamics in established indications rather than patent-driven expansion.

What is the current clinical trials status for cefuroxime axetil?

Public clinical trial registries show cefuroxime axetil activity largely in older cohorts and in non-pivotal work (bioequivalence, observational studies, or limited protocol trials). As of the latest publicly indexed registry snapshots, there is no clear, ongoing Phase 3 program that would qualify as a registration-defining development update for a new cefuroxime axetil product profile.

Clinical development profile by trial type (publicly visible)

Trial category	Typical purpose	Evidence level visible in registries	Implication
Bioequivalence	Generic bridge to originator dosing	Common in older/ongoing records	Supports generics, not new clinical differentiation
Observational / practice studies	Real-world use patterns	Sporadic	Minimal impact on IP value or premium pricing
Non-pivotal exploratory trials	Smaller clinical cohorts	Limited	Not registration-defining for new indications

What this means for “clinical trials update”

• There is no evidence in public registries of a registration-defining Phase 3 program for cefuroxime axetil that would materially change the market outlook.
• The practical clinical update is driven by antimicrobial stewardship guidance, resistance trends, and competitive positioning among oral cephalosporins and alternatives, not by new cefuroxime axetil clinical efficacy differentiation.

How big is the market for cefuroxime axetil, and what drives it?

Cefuroxime axetil sits inside the broader oral cephalosporin and oral antibiotic market segments. Growth is constrained by:

• Mature lifecycle and widespread generic availability.
• Antimicrobial stewardship protocols that restrict broad-spectrum prescribing.
• Resistance pressures that shift prescriber preference to other beta-lactams or different classes depending on local guidelines and antibiograms.
• Competitive pricing dynamics across generic cephalosporins.

Market drivers (commercial)

Driver	Direction for cefuroxime axetil	Why it matters commercially
Generic substitution and price erosion	Negative	Forces margin compression and higher volume targets
Guideline adherence and stewardship	Neutral to negative	Favors narrow-spectrum options when appropriate
ENT and respiratory infection incidence	Positive	Baseline demand is tied to respiratory seasonality and community infection burden
Payer/formulary inclusion	Positive	Sustained access supports steady volume
Local resistance patterns	Mixed	Can reduce use where efficacy is undermined, or stabilize use where susceptibility holds

Competitive landscape (immediate substitutability)

Cefuroxime axetil competes against:

• Other oral cephalosporins (class-level interchangeability in many indications).
• Beta-lactam options such as amoxicillin and co-amoxiclav depending on guideline position and local resistance.
• Non-beta-lactam alternatives in penicillin-allergic patients or where stewardship drives narrower choices.

What market projection should investors and R&D planners use?

Given the absence of visible late-stage differentiation, the projection is a “volume and access” model rather than an “innovation-led growth” model. The base case should assume: 1) continued generic availability and price pressure, 2) stable-to-slow volume growth aligned to infection incidence and formulary continuity, 3) margin compression offset by procurement and scale efficiencies.

Projection framework (practical, decision-ready)

Horizon	Expected trend	Primary levers
12 to 24 months	Flat to low single-digit market value growth	Retail and institutional access; seasonality; competitive pricing
3 to 5 years	Low-growth value trajectory, possible unit-volume stability	Generic competitive intensity; stewardship adoption; local resistance
5+ years	Mature market behavior	Limited clinical differentiation; ongoing substitution by lower-cost comparators

Practical numeric projection approach (how to underwrite)

Because cefuroxime axetil is largely generic in most jurisdictions, projections should be underwritten with:

• Net pricing trends (generic tender/wholesale index) and expected annual deflation.
• Estimated share stability in target formularies (where cefuroxime axetil is a listed oral option).
• Changes in prescribing restrictions by stewardship programs.
• Resistance-adjusted utilization assumptions (use rates by region and infection type).

The absence of a visible pivotal pipeline means the most material swing factors are commercial and policy, not clinical trial outcomes.

Where does cefuroxime axetil sit in stewardship and prescribing policy?

Stewardship programs influence cefuroxime axetil indirectly by shifting prescriber behavior toward:

• narrow-spectrum agents when clinically appropriate,
• cultures and susceptibility-guided therapy when feasible,
• restriction of cephalosporins in settings where resistance signals favor different classes.

This is consistent with common stewardship patterns for oral antibiotics used in community respiratory and ENT infections: cefuroxime axetil retains use where guideline positioning matches local susceptibility and where tolerability and dosing convenience support adherence.

Is there any patent or lifecycle tail left that changes the outlook?

Cefuroxime axetil is an established molecule with broad generic availability. Market outlook should therefore be modeled as:

• near-term exposure to generic price compression,
• limited upside from new exclusivity unless a novel formulation or new indication secures regulatory differentiation.

In the absence of a visible Phase 3 program, the “tail” is best treated as a mature lifecycle asset, not an innovation platform.

Clinical trial update checklist for decision-making (what matters now)

For cefuroxime axetil, operational trial monitoring should focus on:

• New bioequivalence submissions for key markets (signals supply continuity and potential entry waves).
• Any registrational filings tied to new fixed-dose combinations or novel formulations (signals potential incremental differentiation).
• Any resubmissions tied to updated dosing schedules or pediatric positioning beyond historical label indications.

Key Takeaways

• Cefuroxime axetil is a mature, off-patent oral antibiotic with public registry activity that is dominated by non-pivotal work.
• No visible registration-defining Phase 3 clinical development update is evident in public trial records.
• Market growth is driven by formulary access, seasonal infection incidence, and stewardship-aligned prescribing, not by new clinical differentiation.
• Projections should assume low-growth value behavior with margin pressure from generic competition; underwriting should be anchored in pricing and share stability rather than pipeline risk-reward.

FAQs

1) What drives cefuroxime axetil demand most?

Seasonal and community incidence of respiratory and ENT bacterial infections, plus formulary access for oral antibiotic options in outpatient settings.

2) Are there new pivotal clinical trials that would expand use?

Publicly visible registries do not indicate an ongoing Phase 3 registration-driving program for cefuroxime axetil.

3) How does generic competition affect market projections?

It creates sustained price deflation risk, so market value growth typically depends on unit volume resilience and continued formulary inclusion.

4) How do stewardship policies impact cefuroxime axetil?

They can reduce broad cephalosporin use by steering prescribers toward narrower-spectrum agents when appropriate, based on local antibiograms.

5) What should be monitored for upside?

Novel formulation differentiation, fixed-dose combinations, or any credible regulatory program that changes label scope rather than additional bioequivalence-only submissions.

---

References

[1] U.S. National Library of Medicine. ClinicalTrials.gov. Search results for “cefuroxime axetil”. https://clinicaltrials.gov/
[2] European Medicines Agency. Product information and assessment documents (cefuroxime axetil-related materials via EMA search portal). https://www.ema.europa.eu/
[3] World Health Organization. Antimicrobial stewardship and resistance guidance (context for prescribing constraints affecting oral antibiotics). https://www.who.int/
[4] NHS / guideline repositories for community respiratory and ENT antibiotic use (stewardship and local prescribing context). https://www.nhs.uk/